[go: up one dir, main page]

WO2023282624A1 - Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif - Google Patents

Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif Download PDF

Info

Publication number
WO2023282624A1
WO2023282624A1 PCT/KR2022/009765 KR2022009765W WO2023282624A1 WO 2023282624 A1 WO2023282624 A1 WO 2023282624A1 KR 2022009765 W KR2022009765 W KR 2022009765W WO 2023282624 A1 WO2023282624 A1 WO 2023282624A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
anchovy
preventing
obesity
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/009765
Other languages
English (en)
Korean (ko)
Inventor
이선희
신유경
김현재
안혜신
나창선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmax Bio Co Ltd
Original Assignee
Cosmax Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmax Bio Co Ltd filed Critical Cosmax Bio Co Ltd
Publication of WO2023282624A1 publication Critical patent/WO2023282624A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2132—Other phenolic compounds, polyphenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/18—Fractionation

Definitions

  • composition for preventing or improving obesity comprising anchovy extract or neochlorogenic acid as an active ingredient.
  • Obesity is a very serious disease that is rapidly increasing in many countries around the world but has no medically effective treatment.
  • the World Health Organization (WHO) defines a body mass index (BMI) of 30 or more as obesity, and the average obesity rate in OECD member countries is 19.5%, and the rate is gradually increasing.
  • Obesity refers to the state of excessive accumulation of fat in the body due to genetic or lifestyle causes, and causes diseases such as adult diseases and chronic degenerative diseases. are doing Secondary complications such as hyperlipidemia, hypertension, arteriosclerosis, diabetes, and fatty liver caused by excessive fat accumulation and social disorders that can be caused by obesity are problems.
  • 3T3-L1 Adipocyte activates many transcription factors during the differentiation process to accumulate fat.
  • Representative differentiation factors include C/EBPa (CCAAT/enhancer binding protein alpha) and PPAR ⁇ (Peroxisome proliferator) induced by it activated receptor gamma).
  • C/EBPa CCAAT/enhancer binding protein alpha
  • PPAR ⁇ Peroxisome proliferator
  • Anchovy ( Adenocaulon himalaicum Edgew.) It is a perennial herb of Compositae, and the leaf part is specified as an edible part in the food raw materials notified by the Ministry of Food and Drug Safety. It is about 50 to 100 cm tall, grows in shaded and humid areas, and has been used for trauma treatment, stopping coughing, and folk remedies such as hemostatic agents and anti-inflammatory agents.
  • anchovy ( Adenocaulon himalaicum Edgew.) extract or neochlorogenic acid has an effect of inhibiting fat formation and reducing body fat, and the present invention has been completed
  • One aspect is anchovy ( Adenocaulon himalaicum Edgew.) Extract; Or to provide a health functional food composition for preventing or improving obesity comprising neochlorogenic acid represented by the following formula (1) or a food chemically acceptable salt thereof as an active ingredient:
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract;
  • a health functional food composition for preventing or improving metabolic diseases comprising neochlorogenic acid represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or to provide a pharmaceutical composition for preventing or treating obesity containing neochlorogenic acid represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or to provide a pharmaceutical composition for preventing or treating metabolic diseases comprising neochlorogenic acid represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or to provide a cosmetic composition for preventing or improving cellulite containing neochlorogenic acid represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
  • Another aspect is an effective amount of an anchovy ( Adenocaulon himalaicum Edgew.) extract; Or to provide a method for preventing, improving or treating obesity or metabolic diseases comprising administering neochlorogenic acid or a pharmaceutically acceptable salt thereof represented by Formula 1 to a subject in need thereof. .
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or, neochlorogenic acid represented by the following formula (1) or a pharmaceutically acceptable salt thereof is used to prepare a composition for preventing, improving or treating obesity or metabolic diseases.
  • neochlorogenic acid represented by the following formula (1) or a pharmaceutically acceptable salt thereof is used to prepare a composition for preventing, improving or treating obesity or metabolic diseases.
  • One aspect is anchovy ( Adenocaulon himalaicum Edgew.) Extract; Or, to provide a health functional food composition for preventing or improving obesity comprising neochlorogenic acid represented by Formula 1 or a food chemically acceptable salt thereof as an active ingredient:
  • the anchovy extract may be an extract extracted by a solvent from the whole aerial part of the tree, a part thereof, or a material derived therefrom.
  • the part may be a tree stem, root, leaf, flower, petal, seed (seed), fruit flesh, fruit skin, or fruit, and preferably may be a leaf.
  • Whole trees, parts thereof, or materials derived therefrom used for extraction may be ground or minced or suitably dried.
  • the anchovy extract can be extracted by any extraction method, such as hot water extraction, solvent extraction, distillation extraction, and supercritical extraction, which have been conventionally used to extract natural plants, and preferably water, organic solvents, or mixed solvents thereof Characterized in that it is extracted as.
  • the organic solvent may be at least one selected from the group consisting of alcohols having 1 to 4 carbon atoms, such as ethanol, methanol, isopropanol, and butanol.
  • the alcohol may contain alcohol.
  • the alcohol concentration of the aqueous alcohol solution is 1 to 99.5 (v / v)%, for example, 10 to 99.5 (v / v)%, 1 to 70 (v / v)%, 1 to 40 (v / v)% , 5 to 50 (v/v)%, 5 to 40 (v/v)%, 10 to 50 (v/v)%, or 10 to 40 (v/v)%.
  • the extraction is 3 to 50 (w / w) times, for example, 3 to 40 (w / w) times, 3 to 30 (w / w) times, 5 to 50 (w / w) times the extraction solvent with respect to the anchovy value /w) times, 5 to 40 (w/w) times, 5 to 30 (w/w) times, or 4 to 40 (w/w) times.
  • it may include adding 3 to 50 kg of the extraction solvent based on 1 kg of the material derived from the anchovy.
  • the extraction may be performed by hot water extraction, immersion extraction, supercritical extraction, subcritical extraction, reflux cooling extraction, steam distillation, high pressure enzymatic digestion, ultrasonic extraction, elution, compression, and the like.
  • the extraction is performed at 4°C to 90°C, such as 4°C to 80°C, 4°C to 70°C, 5°C to 80°C, 10°C to 70°C, 15°C to 70°C or 20°C to 70°C. it may be
  • the extraction time may vary depending on the selected temperature and may be 1 hour to 2 months, for example, 1 hour to 1 month, 1 hour to 10 days, 1 hour to 5 days, 1 hour to 3 days, 1 hour to 2 days. , 1 hour to 1 day, 1 hour to 10 hours, 2 hours to 1 month, 2 hours to 15 days, 2 hours to 10 days, 2 hours to 5 days, 2 hours to 3 days, 2 hours to 2 days, 2 hours to 1 day or 2 hours to 10 hours.
  • the extraction may include mixing the whole anchovy, a part thereof, or a material derived therefrom in the solvent and leaving it for a certain period of time.
  • the standing may include suitable agitation.
  • the extraction may be repeated one or more times, for example 1 to 5 times.
  • plant residues and extracts may be separated by a known method such as filtration.
  • the extraction may also include removing the solvent from the obtained extract by a known method such as concentration under reduced pressure.
  • the extraction may also include preparing a dried extract by drying the obtained extract, such as lyophilization.
  • the neochlorogenic acid may be isolated from the anchovy extract, and specifically, may be a fraction of the anchovy extract.
  • the fraction refers to a material containing a specific component separated from the extract.
  • the neochlorogenic acid may be separated and purified using column chromatography.
  • the chromatography is silica gel column chromatography, HP-20 column chromatography, RP-18 column chromatography, LH-20 column chromatography ( LH-20 column chromatography), high-performance liquid chromatography, or a combination thereof can be selected and used.
  • the anchovy extract or the neochlorogenic acid is 0.0001% to 90.0% by weight, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% by weight based on the total weight of the composition to 30% by weight, 0.01% to 20% by weight, 0.01% to 10% by weight, 0.01% to 5% by weight, 0.05% to 60% by weight, 0.05% to 40% by weight, 0.05% to 30% by weight % by weight, 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight , 0.1% to 20%, 0.1% to 10%, 0.1% to 5%, 5 to 20%, 5 to 18%, 6 to 15%, 8 to 15% or 7 to 10% by weight.
  • the active ingredient may be used in an 0.01% to 90% by weight, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% by weight based on the total weight of the composition
  • the anchovy extract or the neochlorogenic acid may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the anchovy extract and/or the neochlorogenic acid may inhibit lipogenesis or reduce body fat.
  • the present inventors confirmed the effect of the anchovy extract and/or the neochlorogenic acid to inhibit lipogenesis and reduce body fat, thereby effectively preventing or improving obesity, and metabolic diseases caused by obesity can also be effectively prevented or treated. confirmed.
  • the anchovy extract and/or the neochlorogenic acid may promote energy metabolism. It was confirmed that the anchovy extract and / or neochlorogenic acid according to one embodiment promotes phosphorylation of AMPK (AMP-activated protein kinase) and reduces the expression of PPAR ⁇ , C / EBP ⁇ and SREBP-1, promoting energy metabolism By doing so, it was confirmed that obesity and metabolic diseases can be prevented, improved or treated. In addition, it was confirmed that the anchovy extract and/or neochlorogenic acid according to one embodiment also reduced obesity-related hormones such as leptin and insulin, thereby effectively preventing, improving, or treating obesity.
  • AMPK AMP-activated protein kinase
  • the term "obesity” refers to a condition in which body fat is excessive, and generally refers to a case in which body weight is higher than normal, but even if the body weight is not overweight, obesity is diagnosed when the proportion of body fat among body components is high.
  • obesity refers to a disease that affects everyone.
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or, to provide a health functional food composition for preventing or improving metabolic diseases comprising neochlorogenic acid represented by Formula 1 or a food chemically acceptable salt thereof as an active ingredient:
  • metabolic disease may refer to a disease caused by excessive synthesis or accumulation of fat due to abnormal energy metabolism in the body due to various causes such as excessive energy intake or hormonal imbalance.
  • metabolic diseases can be caused by obesity.
  • the type of the metabolic disease is not particularly limited, but may be at least one selected from the group consisting of fatty liver, diabetes, hypertension, hyperlipidemia, hypercholesterolemia, dyslipidemia, and arteriosclerosis.
  • acceptable means exhibiting properties that are not toxic to cells or humans exposed to the composition.
  • acceptable salt refers to a salt prepared using a specific compound according to one aspect with a relatively non-toxic acid or base.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include salts of sodium, potassium, calcium, ammonium, organic amines, or magnesium or similar salts.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of an acid in neat solution or in a suitable inert solvent.
  • Pharmaceutically acceptable acid addition salts include salts of inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogen carbonate ion, phosphoric acid, hydrogen phosphate ion, dihydrogen phosphate ion, sulfuric acid, hydrogen sulfate ion, hydroiodic acid or phosphorous acid; and salts of organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, and methanesulfonic acid. and salts of amino acids (eg, arginine) and salts of organic acids such as glucuronic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid
  • the acceptable salts can be synthesized by conventional chemical methods from parent compounds containing acidic or basic moieties. Generally, these salts are prepared by reacting the free acid or base form of these compounds with an appropriate stoichiometric amount of the base or acid, either in water or in an organic solvent or in a mixture of the two. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
  • the “health functional food” refers to a food manufactured and processed by extracting, concentrating, refining, mixing, etc., a specific ingredient as a raw material or a specific ingredient contained in a food raw material for the purpose of supplementing health. It refers to food designed and processed to sufficiently exert biological control functions such as defense, regulation of circadian rhythm, prevention and recovery of disease, etc.
  • the health functional food composition may perform functions related to prevention and improvement of obesity and prevention and improvement of metabolic diseases.
  • the health beverage composition of the present invention may include various flavoring agents or natural carbohydrates as additional components, like conventional beverages.
  • the aforementioned natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, and synthetic sweeteners such as saccharin and aspartame.
  • the proportion of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
  • the health functional food may include food additives acceptable in food science, and may include appropriate carriers commonly used in the manufacture of health functional food.
  • the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages; and the like.
  • the composition of the present invention may include fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not critical, but is generally selected in the range of 0.01 to 0.1 part by weight per 100 parts by weight of the composition of the present invention.
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or providing a pharmaceutical composition for preventing or treating obesity comprising neochlorogenic acid or a pharmaceutically acceptable salt thereof represented by Formula 1 below as an active ingredient:
  • Another aspect is anchovy ( Adenocaulon himalaicum Edgew.) extract; Or providing a pharmaceutical composition for preventing or treating metabolic diseases comprising neochlorogenic acid represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
  • Another aspect is an effective amount of an anchovy ( Adenocaulon himalaicum Edgew.) extract; Or, it provides a method for preventing, improving or treating obesity or metabolic disease, comprising administering neochlorogenic acid represented by Formula 1 or a food chemically acceptable salt thereof to a subject in need thereof.
  • anchovy Adenocaulon himalaicum Edgew.
  • neochlorogenic acid represented by Formula 1 or a pharmaceutically acceptable salt thereof is used for preparing a composition for preventing, improving or treating obesity or metabolic diseases.
  • the metabolic disease may be one or more selected from the group consisting of fatty liver, diabetes, hypertension, hyperlipidemia, hypercholesterolemia, dyslipidemia, and arteriosclerosis.
  • composition can refer to a molecule or compound that imparts some beneficial effect upon administration to a subject.
  • beneficial effects may include enabling diagnostic determination; amelioration of a disease, symptom, disorder or condition; reducing or preventing the occurrence of a disease, condition, disorder or condition; and responding to a disease, symptom, disorder or condition in general.
  • the pharmaceutical composition may give a beneficial effect on obesity and metabolic diseases.
  • prevention refers to partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its attendant symptoms, preventing the acquisition or re-acquisition of a disease or disorder, or the risk of acquiring a disease or disorder. tells how to reduce For example, the prevention refers to any action that inhibits or delays the occurrence of obesity and metabolic disease symptoms by administration of the composition according to the present invention.
  • treatment includes inhibition, alleviation or elimination of the development of diseases such as obesity and metabolic diseases.
  • improvement may refer to any action that at least reduces the severity of parameters associated with alleviation or treatment of conditions, such as obesity and metabolic disease symptoms.
  • the pharmaceutical composition can be administered parenterally during clinical administration and can be used in the form of a general pharmaceutical preparation.
  • Parenteral administration may refer to administration through an administration route other than oral, such as rectal, intravenous, peritoneal, intramuscular, arterial, transdermal, nasal, inhalation, ocular and subcutaneous administration.
  • the pharmaceutical composition of the present invention may additionally contain one or more active ingredients exhibiting the same or similar functions.
  • Types of pharmaceutically active ingredients capable of delivering the active ingredient into the subject include anticancer agents, contrast agents (dye), hormones, anti-hormonal agents, vitamins, calcium agents, mineral preparations, saccharide preparations, organic acid preparations, protein amino acid preparations, detoxifying agents, and enzymes.
  • Preparations metabolic preparations, diabetes concomitant medicines, tissue regeneration medicines, chlorophyll preparations, pigment preparations, tumor medicines, tumor treatment agents, radiopharmaceuticals, tissue cell diagnostic agents, tissue cell therapy agents, antibiotics preparations, antiviral agents, complex antibiotics preparations, chemicals Therapeutic agents, vaccines, toxins, toxoids, antitoxins, leptospira serum, blood products, biological agents, analgesics, immunogenic molecules, antihistamines, allergy medications, non-specific immunogenic agents, anesthetics, stimulants, psychoactive agents, small molecule compounds, nucleic acids, It may include aptamers, antisense nucleic acids, oligonucleotides, peptides, siRNAs, and micro RNAs.
  • the pharmaceutical composition may be prepared by further including one or more pharmaceutically acceptable carriers.
  • a pharmaceutically acceptable carrier may be a mixture of saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, and, if necessary, antioxidants and buffers.
  • bacteriostatic agents and other conventional additives may be added.
  • diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare formulations for injections such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
  • it can be preferably formulated according to each disease or component by an appropriate method in the art.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • Witepsol, Macrogol, Tween 61, cacao butter, liurine fat, glycerogeratin and the like may be used as a base for the suppository.
  • the pharmaceutical composition may include carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, and small molecules in order to increase stability or absorption. Proteins or other Stabilizers can be used as pharmaceuticals.
  • Another aspect provides a method of treating obesity and metabolic disease comprising administering the pharmaceutical composition to a subject.
  • administering means providing a pharmaceutical composition to a subject by any suitable method.
  • a pharmaceutically effective amount and an effective dosage of the pharmaceutical composition may vary depending on the formulation method, administration method, administration time and/or route of administration of the pharmaceutical composition.
  • the type and degree of response to be achieved by administration of the pharmaceutical composition, the type of subject to be administered, age, weight, general health condition, symptom or degree of disease, gender, diet, excretion, simultaneous or It may vary according to various factors including drugs and other components of the composition used together in this case, and similar factors well known in the medical field.
  • a person of ordinary skill in the art can readily determine and prescribe an effective dosage for the desired treatment.
  • Administration of the pharmaceutical composition according to the present invention can be administered once a day, divided into several administrations. Therefore, the dosage is not intended to limit the scope of the present invention in any way.
  • the dosage of the pharmaceutical composition may be 1 ug/kg/day to 1,000 mg/kg/day.
  • the subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat.
  • the subject may be an individual who needs a cure for obesity and metabolic disease or has a desire to lose weight.
  • a cosmetic composition for preventing or improving cellulite comprising neochlorogenic acid represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient is provided:
  • cellulite refers to a condition in which fat protrudes in places, especially in the thigh or buttocks, due to circulatory disorders due to the accumulation of excessive fat and waste products.
  • the cause of cellulite is basically the increase or hypertrophy of fat cells.
  • prevention or improvement of cellulite may mean reducing the volume of cellulite, reducing the height of cellulite, removing cellulite, flattening cellulite and its surroundings, and the like. there is.
  • the composition has an effect of inhibiting body fat accumulation and thus has an effect of preventing or improving cellulite.
  • the composition has a body slimming effect.
  • body slimming refers to promoting even redistribution of fat, reducing the volume of a body or a part of the body, eliminating puffiness as a result, in body lines that appear bumpy due to uneven distribution of fat under the skin. It may mean reducing the volume of the body or a part of the body, improving the state of local obesity, dissolving and excreting fat in fat cells, reducing triglyceride and body fluid accumulation in fat cells, and the like.
  • the cosmetic composition includes lotion (skin lotion), toner, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, hand sanitizer, foundation, essence, Nutritional essence, packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, suspensions, gels, powders, pastes, mask packs, and can be prepared into formulations including sheets. Compositions of such formulations may be prepared according to conventional methods in the art. The blending amount of the additional ingredients such as the moisturizing agent can be easily selected by those skilled in the art within a range that does not impair the objects and effects of the present invention.
  • the cosmetic composition may further include functional additives and ingredients included in general cosmetic compositions in addition to the active ingredients disclosed herein, and commonly used purified water, thickeners, preservatives, stabilizers, solubilizers, surfactants, carriers, A flavoring agent or a combination thereof may be further included.
  • the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts.
  • Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, UV scattering agents, UV absorbers, coloring agents, perfumes, and the like may be exemplified as the carrier.
  • Compounds/compositions that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, humectant, viscosity modifier, emulsion, stabilizer, UV scattering agent, UV absorber, coloring agent, fragrance, etc. are already known in the art. Since there is, those skilled in the art can select and use an appropriate corresponding material / composition.
  • composition containing anchovy ( Adenocaulon himalaicum Edgew.) extract or neochlorogenic acid according to one aspect as an active ingredient, it has the effect of inhibiting fat accumulation and reducing body fat, making it useful for obesity and metabolic diseases.
  • 1 is a separation diagram of neochlorogenic acid derived from anchovy extract.
  • Figure 5a is a graph showing the cytotoxicity of the anchovy extract
  • Figure 5b is a graph showing the fat accumulation inhibitory effect of anchovy extract.
  • Figure 6a is a graph showing the cytotoxicity of neochlorogenic acid
  • Figure 6b is a graph showing the fat accumulation inhibitory effect of neochlorogenic acid.
  • Figure 7 is a photograph showing the fat reduction effect of anchovy extract in zebrafish induced obesity.
  • Figure 8 is a graph showing that there is no change in the body length of the zebrafish when anchovy extract is administered to the zebrafish in which obesity is induced.
  • Figure 9 is a graph showing the effect of reducing the body weight of zebrafish when anchovy extract is administered to zebrafish in which obesity is induced.
  • FIG. 10 is a graph showing the effect of reducing the abdominal circumference of zebrafish when anchovy extract is administered to zebrafish whose obesity is induced.
  • 11 is a graph showing the effect of reducing fat accumulated in the liver of zebrafish when anchovy extract is administered to zebrafish whose obesity is induced.
  • Figure 12 is a graph showing the change in body weight when the anchovy extract was administered simultaneously with the induction of obesity in mice.
  • Figure 14a is a graph showing the weight of body fat when the anchovy extract was administered simultaneously with the induction of obesity in mice; And Figure 14b is a graph showing the fat content in the body when the anchovy extract was administered simultaneously with the induction of obesity in mice.
  • Figure 15a is a graph showing the weight of subcutaneous fat when anchovy extract was administered simultaneously with induction of obesity in mice; 15B is a graph showing liver weight; 15C is a graph showing mesenteric fat weight; 15D is a graph showing brown fat weight; 15E is a graph showing epididymal fat weight; and Figure 15f is a graph showing the renal fat weight.
  • FIG. 16a is a photograph of adipocytes observed under a microscope to see the effect of anchovy extract on reducing the size of fat globules; and FIG. 16B is a graph showing the size of adipocytes.
  • Figure 17a is the result of confirming the expression of p-AMPK protein in mouse adipose tissue when the anchovy extract was administered; and FIG. 17b shows the results of confirming the expression of PPAR- ⁇ , C/EBPa, and SREBP-1 proteins.
  • Figure 18a is a graph analyzing leptin content in mouse plasma when anchovy extract was administered; And Figure 18b is a graph analyzing the insulin content.
  • Figure 19a is a graph analyzing the total cholesterol content in mouse plasma when anchovy extract was administered; And Figure 19b is a graph analyzing the content of low-density cholesterol.
  • Anchovy extract contained in the composition of the present invention is prepared by the following process. First, after purchasing an anchovy that grows wild in Korea, washing it with distilled water, it was completely dried in a cool place without sunlight until there was no change in weight. After that, after preparing 600 kg of 30% fermented alcohol (30 times, w/w) in the completely dried dried product, 20 kg of the dried product was added. At this time, the mixing ratio of the dry matter and 30% fermented alcohol was 30 times the weight ratio. Next, 30% fermented alcohol mixed with the dried product was put in a constant temperature water bath and stirred and extracted at 60 ° C. for 5 hours. The extracted sample was filtered through a housing filter (10 um) and then concentrated under reduced pressure to obtain a yellow-brown water-soluble powder.
  • Example 2 200 g of the extracted powder obtained in Example 1 was subjected to gel filteration using DIAION HP-20 resin.
  • Example 1 of the present invention The extracted powder and neochlorogenic acid obtained in Example 1 of the present invention were analyzed by high performance liquid chromatography (HPLC) and ultraviolet absorbance detector (UV/Vis detector).
  • HPLC high performance liquid chromatography
  • UV/Vis detector ultraviolet absorbance detector
  • Waters e2695 Series system, Waters 24489 UV/Vis detector (Worcester, MA, USA), and X select C18 (5 ⁇ m, 250 ⁇ 4.6 mm, waters, Milford, Massachusetts, USA) column were used for the HPLC instrument. All solvents were prepared by J.T. HPLC grade solvents purchased from Baker (Phillipsburg, NJ, USA) were used.
  • the temperature of the column was set to 35°C
  • the injection volume was 20 ⁇ l
  • the measurement wavelength was set to 325 nm.
  • acetonitrile ACN
  • tertiary distilled water D.W
  • formic acid 0.1% formicacid ACN -0.1% formicacid D.W (1:9 - 10:0, v /v)
  • the mixed solution was analyzed for 60 minutes.
  • 1 g of the extracted powder obtained in Example 1 was precisely weighed, 100 ml of 30% methanol was added, dissolved in an ultrasonic shaker for 30 minutes, cooled at room temperature, and the supernatant was taken and filtered through a 0.22 ⁇ m membrane filter.
  • Neochlorogenic acid 10 mg of silver was precisely weighed, added with 20 ml of 50% methanol, dissolved in an ultrasonic shaker for 30 minutes, allowed to cool at room temperature, and then filtered with a 0.22 ⁇ m membrane filter after adding methanol. Chromatograms were extracted at 325 nm for each analysis sample, and the anchovy extract peak and neochlorogenic acid peak were compared and analyzed and shown in FIG. 4.
  • the cytotoxicity of the anchovy extract of Example 1 and neochlorogenic acid of Example 2 on epidermal cells was measured.
  • 3T3-L1 was attached to a 96-well plate at a concentration of 1.0 X 10 4 cells/well for 24 hours and stabilized. Thereafter, each concentration sample was replaced with the treated medium and cultured for 24 hours. Then, the degree of cell viability was measured by MTT assay.
  • zebrafish fry were prepared by inviotec. First, females and males were placed in a 1:1 ratio in a tank equipped with a net to separate eggs and adult fish, and zebrafish embryos were collected after 12 hours. After collection, it was washed three times using 0.03% sea salt solution to remove foreign substances and reared in an incubator with a 28.5 ° C photoperiod (14 light / 10 dark).
  • Zebrafish fry (3 dpf) after 3 days of fertilization were placed in a petri dish, and then treated for 2 days of rotifer, 6 days of artemia, and 4 days of feed, for a total of 12 days, to prepare an overfeed-induced obese zebrafish model.
  • the overfeed-induced obese zebrafish model was treated with rotifer, artemia, and feed 4 times a day, and the normal control group was treated with rotifer, artemia, and feed twice a day. From the 11th day, the overfeed-induced obese zebrafish model was treated with 100 ⁇ g/ml of anchovy extract and 50 ⁇ g/ml of Cissus extract as a positive control, and exposed for 24 hours.
  • Example 2 In order to confirm whether the weight and fat of zebrafish decreased when the anchovy extract obtained in Example 1 was administered, an experiment was performed as follows. After the experiment was completed, the zebrafish fry were anesthetized with 0.02% tricaine, and the body length and belly length of the zebrafish were observed using an optical microscope (Olympus 1 ⁇ 70, Olympus, Japan). Afterwards, body length and belly length were measured using Focus Lite software, and the weight was checked with a precise electronic scale for analysis and graphed. Statistical analysis was performed using Sigma Plot software (Systat software Inc., USA) and paired t-teat and repeated ANOVA to confirm whether there was a difference between groups in each experimental condition.
  • anchovy extract can effectively prevent or improve obesity by inhibiting fat accumulation, and also effectively prevent or treat metabolic diseases caused by obesity.
  • Example 1 When the anchovy extract of Example 1 was administered, the following experiment was performed to confirm the reduction of fatty liver in the liver of zebrafish in which obesity was induced.
  • the sacrificial zebrafish fry at the end of the experiment were fixed in 4° C. paraformaldehyde (PFA) overnight, and then washed twice with 1X PBS. Thereafter, 80% and 100% propylene glycol were sequentially treated for 20 minutes at room temperature, and zebrafish fry were dyed by exposing overnight to 0.5% Oil Red O in 100% propylene glycol at room temperature to block light.
  • PFA paraformaldehyde
  • the dyed fry was washed with 1 X PBS, treated with 100% and 80% propylene glycol at room temperature for 30 minutes, respectively, to wash the dye, stored in 80% propylene glycol at 4°C, and examined under an optical microscope (Olympus 1 ⁇ 70, Olympus , Japan) was used to observe liver fat, and fat size was measured using Focus Lite software.
  • an obese animal model was first prepared. 8-week-old male C57BL/6N mice (specific-pathogen-free (SPF) grade, 20 ⁇ 2 g, Orient Bio) were set into 5 groups as follows, and 8 mice per group were tested: As a normal control, high-fat diet Orlistat, an anti-obesity treatment, was placed in a normal mouse (con), which was not administered with anything, and an obese mouse (HFD), which was induced with a 30% high-fat diet and not administered anything, respectively. was orally administered. As an experimental group, 100 mg/kg and 300 mg/kg of anchovy extract were orally administered to obese mice, respectively. The anchovy extract was orally administered 5 days per week during the administration period. The dark: light cycle was maintained at 12-hour: 12-hour intervals, and water was freely consumed.
  • SPPF specific-pathogen-free
  • the weights of various adipose tissue and liver tissue analyzed after animal sacrifice were all increased when the high-fat diet was administered, but it was confirmed that the weight of the anchovy extract was significantly decreased in the group administered with the anchovy extract (FIG. 15).
  • the group administered with 300 mg/kg of anchovy extract showed a degree of reduction similar to that of the positive control group, indicating that the anchovy extract can effectively prevent or improve obesity by suppressing fat accumulation.
  • mouse epididymal adipose tissue was fixed in 4% paraformalin. After dehydration through continuous alcohol concentration gradient (Graded alcohol series) and washing several times, the tissues were embedded in paraffin. Tissue sections were cut to a thickness of 4 ⁇ m, and stained with hematoxylin and eosin. In order to confirm the size of white adipocytes, the area of each adipocyte was measured in each section using CellSence software (Olympus Co., USA). As a result, it was confirmed that the size of adipocytes in the group administered with the anchovy extract along with induction of obesity was reduced to a degree similar to that of the normal control group (FIG. 16).
  • AMPK AMP-activated protein kinase
  • C/EBPs proteins involved in adipogenesis including C/EBP ⁇ , peroxisome proliferator-activated receptor (PPAR) ⁇ , and sterol controlled element-binding protein (SREBP)-1. It promotes terminal differentiation by increasing the expression of transcription factors that regulate genes.
  • the protein expression level of the group administered with the anchovy extract along with induction of obesity was analyzed.
  • the supernatant was obtained by centrifugation at 4 ° C. and 15,000 rpm for 30 minutes, and then a standard curve was prepared using the Bradford method to quantify the protein.
  • electrophoresis was performed using a 10% SDS-PAGE gel, followed by immunoblotting on a PVDF membrane for 1 hour and 20 minutes.
  • TBST buffer solution Tris-buffered saline-Tween 20
  • anti-p-AMPK, PPAR ⁇ , C/EBP ⁇ , and SREBP-1 antibodies were added at 1:1000. and reacted at 4°C for 18 hours.
  • the cells were reacted with peroxidase-conjugated secondary antibodies at room temperature for 2 hours.
  • color development and development with a hyper film using an enhanced chemiluminescence kit (Amersham Life Sciences, Amersham, U.K.) The protein changes in each control and experimental group were confirmed by western blot.
  • anchovy extract effectively prevents or improves obesity through the induction of AMPK phosphorylation, which is important for the anti-obesity effect, and the mechanism of reducing PPAR ⁇ , C/EBP ⁇ , and SREBP-1, and also effectively prevents metabolic diseases caused by obesity. that it can be prevented or cured.
  • Leptin a hormone produced primarily by fat cells, plays a role in suppressing food intake, thereby regulating energy balance under normal conditions. However, if you are obese, your sensitivity to leptin is reduced, so you do not feel full even if your leptin level is high. Insulin is secreted by the pancreas and is an important hormone for the synthesis and storage of energy substances. In the case of obesity, due to insulin resistance, the cells do not recognize insulin well and become less sensitive and secrete more insulin.
  • the blood biochemistry test of the group administered with the anchovy extract along with obesity induction was performed using a biochemistry analyzer (AU480 Chemistry Analyzer, Beckman coulter, CA, USA). performed.
  • a biochemistry analyzer AU480 Chemistry Analyzer, Beckman coulter, CA, USA.
  • Example 5 For the anchovy extract of Example 1 and neochlorogenic acid of Example 2, the ingredients in Table 5 below were mixed and tableted according to a conventional tablet manufacturing method to prepare tablets.
  • Example 6 For the anchovy extract of Example 1 and neochlorogenic acid of Example 2, the ingredients in Table 6 below were mixed according to a conventional capsule preparation method and filled into gelatin capsules to prepare soft capsules.
  • Example 7 With respect to the anchovy extract of Example 1 and neochlorogenic acid of Example 2, the ingredients in Table 7 below were mixed according to a beverage manufacturing method suitable for taste and filled into a bottle or pouch to prepare a liquid formulation.
  • Example 8 For the anchovy extract of Example 1 and neochlorogenic acid of Example 2, the ingredients in Table 8 were mixed according to the jelly manufacturing method suitable for the taste and filled in three cotton cloths to prepare jelly.
  • raw material name unit weight (g) raw material name unit weight (g)
  • Example 1 2.0000
  • Example 2 0.5000 food gel 0.3600 food gel 0.3600 carrageenan 0.0600 carrageenan 0.0600 calcium lactate 0.1000 calcium lactate 0.1000 sodium citrate 0.0600 sodium citrate 0.0600 complex gold extract 0.0200 complex gold extract 0.0200
  • Enzymatically Treated Stevia 0.0440 Enzymatically Treated Stevia 0.0440 fructooligosaccharide solution 5.0000 fructooligosaccharide solution 5.0000 Red Grape Concentrate 2.4000 Red Grape Concentrate 2.4000 Purified water 13.9560 Purified water 15.4560
  • a nourishing cream was prepared according to the conventional method with the composition shown in Table 9 below.
  • composition ratio is generally prepared as a formulation example by mixing suitable ingredients, the mixing ratio and raw materials may be arbitrarily changed as necessary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou atténuer l'obésité comprenant un extrait d'Adenocaulon himalaicum ou de l'acide néochlorogénique en tant que principe actif. La composition comprend un extrait d'Adenocaulon himalaicum ou de l'acide néochlorogénique en tant que principe actif, et selon un aspect, a pour effet d'inhiber l'accumulation de graisse et de réduire la graisse corporelle, et peut être efficacement utilisée pour l'obésité et les maladies métaboliques.
PCT/KR2022/009765 2021-07-08 2022-07-06 Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif Ceased WO2023282624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0089987 2021-07-08
KR1020210089987A KR102686913B1 (ko) 2021-07-08 2021-07-08 멸가치 추출물 또는 네오클로로겐산을 유효성분으로 포함하는 비만 예방 또는 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2023282624A1 true WO2023282624A1 (fr) 2023-01-12

Family

ID=84800807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/009765 Ceased WO2023282624A1 (fr) 2021-07-08 2022-07-06 Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif

Country Status (2)

Country Link
KR (1) KR102686913B1 (fr)
WO (1) WO2023282624A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240139236A (ko) 2023-03-14 2024-09-23 국립안동대학교 산학협력단 멸가치 추출물을 유효성분으로 포함하는 면역증진용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287655A1 (en) * 2008-10-31 2016-10-06 Naturex, S.A. Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
US20190111015A1 (en) * 2017-10-12 2019-04-18 Vidya Herbs, Inc. Chlorogenic acid composition for the treatment of metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102189416B1 (ko) 2019-02-11 2020-12-11 코스맥스바이오 주식회사 금불초 복합추출물을 유효성분으로 함유하는 비만 예방 및 체지방 감소용 조성물
KR102444911B1 (ko) * 2019-07-12 2022-09-21 코스맥스바이오 주식회사 산나물 추출물을 유효성분으로 하는 근육관련 질환 예방 또는 치료, 근기능 개선 또는 운동수행능력 개선용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287655A1 (en) * 2008-10-31 2016-10-06 Naturex, S.A. Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
US20190111015A1 (en) * 2017-10-12 2019-04-18 Vidya Herbs, Inc. Chlorogenic acid composition for the treatment of metabolic disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE, YOUNG-MIN;BAE, JI-HYUN;JUNG, HO-YOUNG;KIM, JAE-HYUN;PARK, DONG-SIK: "Antioxidant Activity in Water and Methanol Extracts from Korean Edible Wild Plants", 31 January 2011 (2011-01-31), XP053027318 *
LIU SI-LE, PENG BING-JIE, ZHONG YING-LI, LIU YUN-LONG, SONG ZHUO, WANG ZHENG: "Effect of 5-caffeoylquinic acid on the NF-κB signaling pathway, peroxisome proliferator-activated receptor gamma 2, and macrophage infiltration in high-fat diet-fed Sprague–Dawley rat adipose tissue", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 6, no. 8, 1 January 2015 (2015-01-01), GB , pages 2779 - 2786, XP093020686, ISSN: 2042-6496, DOI: 10.1039/C5FO00626K *
NARITA YUSAKU, INOUYE KUNIYO: "Degradation Kinetics of Chlorogenic Acid at Various pH Values and Effects of Ascorbic Acid and Epigallocatechin Gallate on Its Stability under Alkaline Conditions", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 4, 30 January 2013 (2013-01-30), US , pages 966 - 972, XP093020685, ISSN: 0021-8561, DOI: 10.1021/jf304105w *

Also Published As

Publication number Publication date
KR102686913B9 (ko) 2024-12-10
KR20230010116A (ko) 2023-01-18
KR102686913B1 (ko) 2024-07-23

Similar Documents

Publication Publication Date Title
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2020166779A1 (fr) Composition pour l'inhibition de la formation de graisse et la réduction de la graisse corporelle, contenant de l'hydrangénol en tant que principe actif
CN113350232B (zh) 含马齿苋、艾叶及红景天的混合提取物作为有效成分的皮肤保护及刺激缓解用化妆品组合物
JP7303582B2 (ja) インディアングーズベリー抽出物と大麦若葉抽出物との複合物（ｉｂ複合物）を有効成分として含む肥満及び／または糖尿を伴うメタボリックシンドロームの予防、改善治療用組成物
KR20220155464A (ko) 신규한 비피도박테리움 롱검 균주 및 이의 용도
KR101908221B1 (ko) 금방동사니 추출물을 포함하는 항비만 조성물
WO2023282624A1 (fr) Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif
WO2020256464A1 (fr) Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production
KR102110903B1 (ko) 엉겅퀴 꽃 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물
EP3189846A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2013012117A1 (fr) Utilisation de compositions pharmaceutiques comprenant un phytostérol pour prévenir ou traiter les maladies inflammatoires
EP3097920A1 (fr) Composition médicale comprenant un extrait de stauntonia hexaphylla
WO2023080725A1 (fr) Composition comprenant cassia mimosoides var. nomame en tant que principe actif pour favoriser ou améliorer le métabolisme énergétique
WO2023080726A1 (fr) Composition destinée à favoriser ou à améliorer le métabolisme énergétique contenant, en tant que principe actif, un extrait d'eisenia bicyclis ou du 2-phloroeckol
KR102891686B1 (ko) 차풀 추출물을 유효성분으로 포함하는 에너지 대사 촉진 또는 개선용 조성물
KR102891685B1 (ko) 대황 추출물 또는 2-phloroeckol을 유효성분으로 포함하는 에너지 대사 촉진 또는 개선용 조성물
KR102137144B1 (ko) 피라칸타 잎 추출물을 포함하는 항염증용 조성물
KR102896901B1 (ko) 아피게닌-7-오-글루크로나이드를 유효성분으로 포함하는 비만 예방 또는 개선용 조성물
KR102802428B1 (ko) 2,3,4,5-테트라카페오일글루카릭 엑시드를 유효성분으로 하는 비만 예방 또는 개선용 조성물
WO2020246863A1 (fr) Composition comprenant du chlorhydrate de cudrania comme composant efficace pour soulager, traiter ou prévenir les maladies musculaires, ou améliorer les fonctions musculaires
WO2023277626A1 (fr) Composition pour l'amélioration de la peau, comprenant du 2-phloroeckol en tant que principe actif
KR102754013B1 (ko) 멸가치 추출물 또는 네오클로로겐산을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 예방 또는 개선용 조성물
KR102482196B1 (ko) 천심련 추출물 또는 안드로그라폴라이드를 유효성분으로 포함하는 일주기 리듬 장애 예방 또는 개선을 위한 조성물
KR101501339B1 (ko) 머루근 추출물을 포함하는 미백용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22837976

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22837976

Country of ref document: EP

Kind code of ref document: A1